EAM Investors’s Sagimet Biosciences SGMT Stock Holding History

EAM Investors’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-63,413	Closed	-$483K	–	327
2025 Q2	$483K	Buy	+63,413	New	+$268K	0.07%	211

Other funds holding SGMT

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

EAM Investors's SGMT Position: Q3 2025 in Review

EAM Investors sold out of Sagimet Biosciences (SGMT) in Q3 2025, closing a stake of 63,413 shares — an estimated $483K sold.

EAM Investors first reported a position in SGMT in Q2 2025 and held it in 1 quarter. The position peaked at $483K in Q2 2025. 72 funds tracked by Wall St. Rank hold SGMT as of Q3 2025.

EAM Investors reported no remaining Sagimet Biosciences position as of Q3 2025 after selling out during the quarter.
EAM Investors sold 63,413 Sagimet Biosciences shares in Q3 2025, an estimated $483K.
EAM Investors first reported a position in Sagimet Biosciences in Q2 2025 and held it in 1 quarter.
EAM Investors's Sagimet Biosciences position peaked at $483K in Q2 2025.
72 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2025.

Based on EAM Investors's 13F filing for Q3 2025, filed 14 Nov 2025.